KILIÇ, L. Et Al. 2017. Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis. ACR/ARHP 2017 , (San Diego, United States Of America), 1-4481.

KILIÇ, L., KÜÇÜKŞAHİN, O., ÖZBALKAN, Z., BES, C., YAZISIZ, V., YAZICI, A., ... SOLMAZ, D.(2017). Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis . ACR/ARHP 2017 (pp.1-4481). San Diego, United States Of America

KILIÇ, LEVENT Et Al. "Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis," ACR/ARHP 2017, San Diego, United States Of America, 2017

KILIÇ, LEVENT Et Al. "Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis." ACR/ARHP 2017 , San Diego, United States Of America, pp.1-4481, 2017

KILIÇ, L. Et Al. (2017) . "Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis." ACR/ARHP 2017 , San Diego, United States Of America, pp.1-4481.

@conferencepaper{conferencepaper, author={LEVENT KILIÇ Et Al. }, title={Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis}, congress name={ACR/ARHP 2017}, city={San Diego}, country={United States Of America}, year={2017}, pages={1-4481} }